I am willing to answer this question, but until we get the strategic update I can’t calculate it. Once we get the update I will share my thoughts.
I can add that the Triangle report was extremely conservative and drugs tend to sell for 3-5x peak annual sales. This would imply just for the cardioprotection program a sale price of US$25 to $50 billion (A$40 to $80 billion). Given there are 163 million shares on issue I will let you guys do the maths on the SP.
Ann: EMD AML MDS Trial Expands to Europe, page-47
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.050(3.08%) |
Mkt cap ! $287.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.64 | $210.4K | 125.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 595 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |